StreetAlpha.app
Home › Stocks › EDIT

Editas Medicine, Inc. (EDIT)

Healthcare
$1.64
▼ −4.09%
LAST CLOSE · NOV 20

Editas Medicine develops CRISPR-based gene editing medicines for serious diseases from Cambridge, Massachusetts. It last closed at $1.64 on Nov 20, down 4.09% on the day. The next earnings report for EDIT is expected around Mon, Mar 8, 2027. For the quarter ended Sep 2026, EDIT reported EPS of -$0.15 on revenue of $10.4M, with revenue up 37.4% from a year ago. Over its last 8 reports the stock moved an average of 10.3% the session after earnings. Over the last 12 months EDIT insiders bought $0 of stock on the open market and sold $177K, according to SEC Form 4 filings.

AI Auto Pilots
Is EDIT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold EDIT.

Key Stats

Last 12 months
Results
Revenue
$49.8M
+7.4% vs a year ago
Net income
−$72.2M
−145.0% margin
EPS (diluted)
−$0.54
Free cash flow
−$110.5M
−221.7% margin
Valuation
Market cap
$253.1M
154.3M shares
P/E
–
No P/E while losing money
Price to sales
5.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$93.2M
At Sep 30
Debt
$56.8M
At Sep 30
Shareholder equity
$84.5M
Shares outstanding
154.3M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $25.5M$25.5MFY2021FY2022: $19.7M$19.7MFY2022FY2023: $78.1M$78.1MFY2023FY2024: $32.3M$32.3MFY2024FY2025: $40.5M$40.5MFY2025

From EDIT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Mar 8
Estimated date · Time not announced
Reported EPS
-$0.15
Quarter ended Sep 2026
Year ago EPS
-$0.28
Same quarter last year
Revenue
$10.4M
+37.4% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.55Dec '24Mar 2025: -$0.92Mar '25Jun 2025: -$0.63Jun '25Sep 2025: -$0.28Sep '25Dec 2025: $0.00Dec '25Mar 2026: -$0.26Mar '26Jun 2026: -$0.15Jun '26Sep 2026: -$0.15Sep '26Latest -$0.15
Revenue by quarter
Dec 2024: $30.6MDec '24Mar 2025: $4.7MMar '25Jun 2025: $3.6MJun '25Sep 2025: $7.5MSep '25Dec 2025: $24.7MDec '25Mar 2026: $2.8MMar '26Jun 2026: $11.9MJun '26Sep 2026: $10.4MSep '26Latest $10.4M
How EDIT moved after its last 8 reports
Average move the session after a report ±10.3%
Nov 9, 2026Time not announced+7.0%
Aug 5, 2026After the close+5.5%
May 5, 2026Time not announced+1.3%
Mar 9, 2026Time not announced+16.0%
Nov 10, 2025Time not announced+2.0%
Aug 12, 2025After the close+34.5%
May 12, 2025After the close−2.6%
Mar 5, 2025After the close−13.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on EDITStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on EDIT
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on EDIT

Technical Analysis

EDIT · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 44% below its 20 day and 54% below its 50 day average. It is 64% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $1.63, and the nearest resistance the Pivot at $1.68.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 12.8%/day
Key levels
$3.9452 week high+140.2%
$2.75100 day average+67.7%
$2.70200 day average+64.6%
$2.67Swing high (Oct 20)+62.8%
$2.5250 day average+53.7%
$2.3720 day average+44.5%
$1.74Pivot R1+6.1%
$1.68Pivot+2.4%
$1.64Last close
$1.6352 week low−0.6%
$1.59Pivot S1−3.0%
Indicators
RSI (14)28.58Oversold below 30Oversold
MACD-0.24Below its signal lineBearish
Stochastic0.8Near the bottom of its rangeOversold
ADX (14)17.0No clear trend
Williams %R-99.3Oversold below −80, overbought above −20Oversold
CCI (20)-142.1Oversold below −100, overbought above 100Oversold
Rate of change−36.2%Change over 10 sessionsBearish
ATR (14)$0.21Typical daily range, 12.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for EDIT

What happened before

See how EDIT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow EDIT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How EDIT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for EDITHow many large options trades hit EDIT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

EDIT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲107 buying vs 86 selling
  • ▲Held by funds +12.4 pts
  • ▲Funds holding +3
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding221218+1.4%
In funds' top 10110.0%
Held by funds90.4%78.0%+12.4 pts
New / increased32 / 7535 / 77−4.5%
Reduced / sold out56 / 3040 / 24+34.4%
Put/call ratio0.020.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See EDIT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

EDIT Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$177K16 sales · 3 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $15K2026-03 sold $13K2026-06 sold $45K2026-07 sold $13K2026-08 sold $2K2026-09 sold $19K2026-11 sold $70KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 11Linda BurklyEvp, Chief Scientific OfficerSale plan7,814$2.42$19K
Nov 11Gilmore Neil O'NeillCEOSale plan21,164$2.42$51K
Sep 3Gilmore Neil O'NeillCEOSale plan5,124$3.04$16K
Sep 3Linda BurklyEvp, Chief Scientific OfficerSale plan709$3.04$2K
Sep 3Amy ParisonSvp, CFOSale plan453$3.04$1K
Aug 3Amy ParisonSvp, CFOSale plan678$2.58$2K
Every insider buy and sale for EDIT over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See EDIT insider trades →

From SEC Form 4 filings by EDIT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EDIT is in one of them and how their past EDIT trades turned out.

EDIT in the AI portfolios
Loading…

EDIT News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered EDIT in an article yet. Here's the latest on the wider market.

EDIT in the news

EDIT Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed May 19
Who traded EDIT · since 2017
Latest 5 filings of 17
$1K – $15KTraded Apr 10, 2023Filed May 19, 2023
$1K – $15KTraded Apr 14, 2021Filed May 1, 2021
$1K – $15KTraded Mar 2, 2021Filed Apr 1, 2021
$1K – $15KTraded Nov 17, 2020Filed Dec 1, 2020
$1K – $15KTraded May 1, 2020Filed May 31, 2020
PersonTypeAmountTradedFiledDelay
Dan GoldmanD · NYSell$1K – $15KApr 10, 2023May 19, 202339 d
Don BeyerD · VASell$1K – $15KApr 14, 2021May 1, 202117 d
Don BeyerD · VASell$1K – $15KMar 2, 2021Apr 1, 202130 d
Don BeyerD · VABuy$1K – $15KNov 17, 2020Dec 1, 202014 d
Don BeyerD · VASell$1K – $15KMay 1, 2020May 31, 202030 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Editas Medicine

Editas Medicine is a gene editing company based in Cambridge, Massachusetts. It develops medicines that use CRISPR technology to edit DNA inside the body, aiming to treat serious diseases, and its lead experimental candidate targets high cholesterol. The company also licenses its gene editing technology to partners such as Bristol Myers Squibb and Vertex Pharmaceuticals, which use it for medicines in other therapeutic areas.

Headquarters
Cambridge, MA
Founded
2013